BioCentury | Oct 5, 2015
Emerging Company Profile

Picking a PCSK9

...director of the Laboratory of Biochemical Neuroendocrinology at the Institut de Recherches Cliniques de Montréal (IRCM...
...expects to nominate a lead molecule in about two years. Liphorus has a license from IRCM...
...2014 by Sanderling Ventures, Nabil Seidah, Institut de Recherches Cliniques de Montréal (IRCM) University collaborators: IRCM...
BioCentury | Sep 28, 2015
Company News

Nuclea, IRCM deal

...Nuclea and the IRCM plan to develop quantitative mass spectrometry-based assays to determine the progression and...
...Cambridge, Massachusetts, and said it expects to publish data from a validation study next year. IRCM...
...financial terms, and Nuclea did not respond to inquiries. Nuclea Biotechnologies Inc. , Pittsfield, Mass. Institut de Recherches Cliniques de Montreal (IRCM)...
BioCentury | Nov 10, 2014
Company News

IRCM, Liphorus Pharmaceuticals deal

...9 (PCSK9) . The newco plans to develop small molecules against PCSK9 to treat hypercholesterolemia. IRCM...
...tranched series A round based on preclinical milestones. IRCM said financial terms are not disclosed. Institut de Recherches Cliniques de Montreal (IRCM)...
BioCentury | Nov 7, 2014
Financial News

Sanderling backs IRCM spinout Liphorus

...PCSK9 ) to treat hypercholesterolemia. The company licensed IP developed by researchers at the Institut de Recherches Cliniques de Montreal (IRCM)...
...said Liphorus licensed the technology directly from Adaerata LP, a virtual company spun out from IRCM...
BioCentury | May 2, 2013
Distillery Therapeutics

Indication: Cancer

...16, 2013; doi:10.1073/pnas.1213050110 Contact: Jean-François Côté, Montreal Institute of Clinical Research, Montreal, Quebec, Canada e-mail: jean-francois.cote@ircm.qc.ca BC...
BioCentury | Aug 20, 2012
Company News

AmorChem, Institut de Recherches Cliniques de Montreal (IRCM), National Research Council of Canada, Universite de Montreal endocrine/metabolic news

...and the university's Univalor commercialization arm relating to single domain antibody technology. AmorChem, along with IRCM...
...said it would make a C$500,000 ($501,050) investment in a small molecule PCSK9 program at IRCM...
...clinical development and commercialization. AmorChem declined to disclose financial details. AmorChem L.P. , Montreal, Quebec Institut de Recherches Cliniques de Montreal (IRCM)...
BioCentury | Apr 30, 2012
Product Development

PCSK9 bandwagon

...REGN727 and AMG 145. Nabil Seidah, director of the Laboratory of Biochemical Neuroendocrinology at the Institut de Recherches Cliniques de Montreal (IRCM)...
...a small molecule PCSK9 program at the discovery stage in development by Seidah's group at IRCM...
...Cambridge, Mass. Amgen Inc. (NASDAQ:AMGN), South San Francisco, Calif. AmorChem Financial Inc. , Montreal, Quebec Institut de Recherches Cliniques de Montreal (IRCM)...
Items per page:
1 - 7 of 7
BioCentury | Oct 5, 2015
Emerging Company Profile

Picking a PCSK9

...director of the Laboratory of Biochemical Neuroendocrinology at the Institut de Recherches Cliniques de Montréal (IRCM...
...expects to nominate a lead molecule in about two years. Liphorus has a license from IRCM...
...2014 by Sanderling Ventures, Nabil Seidah, Institut de Recherches Cliniques de Montréal (IRCM) University collaborators: IRCM...
BioCentury | Sep 28, 2015
Company News

Nuclea, IRCM deal

...Nuclea and the IRCM plan to develop quantitative mass spectrometry-based assays to determine the progression and...
...Cambridge, Massachusetts, and said it expects to publish data from a validation study next year. IRCM...
...financial terms, and Nuclea did not respond to inquiries. Nuclea Biotechnologies Inc. , Pittsfield, Mass. Institut de Recherches Cliniques de Montreal (IRCM)...
BioCentury | Nov 10, 2014
Company News

IRCM, Liphorus Pharmaceuticals deal

...9 (PCSK9) . The newco plans to develop small molecules against PCSK9 to treat hypercholesterolemia. IRCM...
...tranched series A round based on preclinical milestones. IRCM said financial terms are not disclosed. Institut de Recherches Cliniques de Montreal (IRCM)...
BioCentury | Nov 7, 2014
Financial News

Sanderling backs IRCM spinout Liphorus

...PCSK9 ) to treat hypercholesterolemia. The company licensed IP developed by researchers at the Institut de Recherches Cliniques de Montreal (IRCM)...
...said Liphorus licensed the technology directly from Adaerata LP, a virtual company spun out from IRCM...
BioCentury | May 2, 2013
Distillery Therapeutics

Indication: Cancer

...16, 2013; doi:10.1073/pnas.1213050110 Contact: Jean-François Côté, Montreal Institute of Clinical Research, Montreal, Quebec, Canada e-mail: jean-francois.cote@ircm.qc.ca BC...
BioCentury | Aug 20, 2012
Company News

AmorChem, Institut de Recherches Cliniques de Montreal (IRCM), National Research Council of Canada, Universite de Montreal endocrine/metabolic news

...and the university's Univalor commercialization arm relating to single domain antibody technology. AmorChem, along with IRCM...
...said it would make a C$500,000 ($501,050) investment in a small molecule PCSK9 program at IRCM...
...clinical development and commercialization. AmorChem declined to disclose financial details. AmorChem L.P. , Montreal, Quebec Institut de Recherches Cliniques de Montreal (IRCM)...
BioCentury | Apr 30, 2012
Product Development

PCSK9 bandwagon

...REGN727 and AMG 145. Nabil Seidah, director of the Laboratory of Biochemical Neuroendocrinology at the Institut de Recherches Cliniques de Montreal (IRCM)...
...a small molecule PCSK9 program at the discovery stage in development by Seidah's group at IRCM...
...Cambridge, Mass. Amgen Inc. (NASDAQ:AMGN), South San Francisco, Calif. AmorChem Financial Inc. , Montreal, Quebec Institut de Recherches Cliniques de Montreal (IRCM)...
Items per page:
1 - 7 of 7